Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
South America Brazil Biologics

Brazilian Regulator Consults On Improving Rules For Registering Biosimilars

  • News

Executive Summary

ANVISA, Brazil’s medicines regulator, is asking for feedback on the regulatory pathway for biosimilars.

You may also be interested in...



Brazilian Regulator Extends COVID-19 Measures

Brazil’s medicines regulator is extending COVID-19 era resolutions designed to speed up its evaluation of clinical research in Brazil.

Canada Publishes Real World Evidence Guidance For HTA And Regulatory Decision Making

The new guidance was drawn up through extensive engagement with national and international experts in RWD and RWE, as well as stakeholders in Canada.

EU Pharma Revision Of Hospital Exemptions For ATMPs 'Is Unsatisfactory'

The EU legislative overhaul falls short on dealing with the issue of hospital exemptions for advanced therapies, says the Alliance For Regenerative Medicine.

Table

View full table

Topics

Tags:
South America Brazil Biologics
Latest Headlines

US FDA Complete Response Letter Rates Vary With Sponsor Size

Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?

Supplemental Filings: Califf Discusses Revolving Door; Poll Examines Public Trust In FDA Approvals

Recent And Upcoming FDA Advisory Committee Meetings

See All
UsernamePublicRestriction

Register

PS147358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By